The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study

INTRODUCTION: The adalimumab biosimilar (ADAbio) Amgevita® has a similar efficacy and safety profile as the adalimumab reference (ADA) Humira®. We studied the clinical consequences of a non-medical switch from ADA to ADAbio in adult patients with mainly established rheumatoid arthritis (RA), psoriat...

Descripción completa

Detalles Bibliográficos
Autores principales: van Adrichem, Roxanne C. S., Voorneveld, Hanneke J. E., Waverijn, Geeke J., Kok, Marc R., Bisoendial, Radjesh J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314483/
https://www.ncbi.nlm.nih.gov/pubmed/35655028
http://dx.doi.org/10.1007/s40744-022-00465-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314483/
https://www.ncbi.nlm.nih.gov/pubmed/35655028
http://dx.doi.org/10.1007/s40744-022-00465-6

Ejemplares similares